Franz SchnetzingerDirector Analytical Development at Gyroscope Therapeutics
Franz joined Gyroscope Therapeutics in January 2017 to lead the development of the control strategy of Gyroscope’s AAV gene therapy vector programmes and to coordinate in-house and external analytical method development. He joined from GSK where he led third party analytical development and validation work for two lentiviral based ex-vivo autologous gene therapy programmes whilst supporting the MAA writing process of Strimvelis. Prior to GSK Franz worked at Baxter AG, Austria, where he developed, validated, and executed release methods for vaccines and recombinant proteins.
Franz holds a BSc in Bioengineering & Bioinformatics from University of Applied Sciences Vienna, Austria, and a MSc in Analytical Biotechnology from Cranfield University, UK.